I think it’s fair to say that everyone expected 2024 to be a little wild, given the U.S. presidential election. But what ended up transpiring this year — particularly when it comes to health, medicine, and the life sciences — became more dramatic than I, at least, had expected: a resurgence of the conversation about vaccines, the shooting of UnitedHealthcare CEO Brian Thompson and the ensuing backlash to the insurance industry, upheaval around weight loss drugs, and so much more.
The top First Opinion essays of 2024 show these stories as well as others, including a few hits (human cloning, “Cali sober,” and autism) hanging on from 2023 and one from 2020. The No. 1 story surprised me a bit, but it’s something that, I suspect, a lot of people about to undergo colonoscopies wonder about.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
